Oncology, biopharma growth drive FY26 performance; board recommends ₹36/share dividend Previous Post BP shares fall after chairman Albert Manifold removed over governance concerns Next Post Oberoi Hotels owner EIH reports drop in Q4 profit despite higher revenue as rising costs hit margins Leave a ReplyCancel ReplyYour email address will not be published. Required fields are marked * Name * Email * Website Add Comment * Save my name, email and website in this browser for the next time I comment.Post Comment
